RET and neoplasm: Regorafenib inhibits vascular endothelial growth factor receptors (VEGFRs) to reduce the degree of islet cell inflammation and the mutant oncogenic kinases KIT, B-RAF, and RET to inhibit tumor angiogenesis and tumor cell proliferation [10].